The American Diabetes Association’s Statement on the OMB’s Financial Assistance Proposed Rule

Why It Matters

The proposed rule threatens the continuity of federal funding for critical diabetes research, potentially delaying new treatments for the 155 million Americans affected by diabetes or prediabetes.

Key Takeaways

• OMB proposes rewrite of federal financial assistance guidance.
• E-Verify and English language mandates added for grant recipients.
• ADA warns politicization could hinder diabetes research funding.
• Political appointees may terminate grants based on vague performance metrics.
• Uncertainty may affect NIH and CDC diabetes programs.

Pulse Analysis

The White House Office of Management and Budget released a proposed rule that overhauls the Guidance for Federal Financial Assistance, a set of regulations governing how federal agencies award and monitor grants. The rewrite implements many provisions from President Trump’s August 2025 executive order aimed at tightening oversight of grantmaking. By redefining reporting standards, performance metrics, and the authority of political appointees, the rule could reshape the funding landscape for health‑related agencies such as the Department of Health and Human Services, the National Institutes of Health, and the Centers for Disease Control and Prevention.

The American Diabetes Association (ADA) issued a strong statement warning that the proposed guidance threatens the stability of diabetes research funding. Requiring grant recipients to use the E‑Verify system and to meet new English‑language thresholds adds administrative layers that many nonprofit and academic institutions may struggle to meet. More concerning, the rule gives political appointees discretion to deem compliance with vague performance criteria and to terminate awards, effectively politicizing scientific grants. ADA argues that such uncertainty could stall ongoing clinical trials and delay the development of new therapies for the 155 million Americans living with diabetes or prediabetes.

Beyond the immediate concerns of the diabetes community, the rule could set a precedent for how federal research dollars are allocated across the biomedical sector. If grant continuity becomes contingent on political alignment rather than scientific merit, universities and research hospitals may redirect resources toward compliance rather than discovery. Stakeholders, including industry partners and patient advocacy groups, are likely to lobby for clearer, science‑focused criteria to preserve the pipeline of innovations that drive economic growth and public health improvements. The outcome of the OMB proposal will therefore influence not only diabetes outcomes but also the broader U.S. research ecosystem.